Loading...

We've got a brand new version of Simply Wall St! Try it out

Anteluo Biological Technology

GTSM:6564
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6564
GTSM
NT$1B
Market Cap
6564 Share Price and Events
7 Day Returns
-0.1%
GTSM:6564
-0.1%
TW Pharmaceuticals
-0.6%
TW Market
1 Year Returns
-7.3%
GTSM:6564
10.4%
TW Pharmaceuticals
13.6%
TW Market
6564 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Anteluo Biological Technology (6564) -0.1% 4.9% 3.5% -7.3% - -
TW Pharmaceuticals -0.1% 2% 4% 10.4% -7.6% -26.4%
TW Market -0.6% 0.8% 7.3% 13.6% 22.8% 24.6%
1 Year Return vs Industry and Market
  • 6564 underperformed the Pharmaceuticals industry which returned 10.4% over the past year.
  • 6564 underperformed the Market in Taiwan, Province of China which returned 13.6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Anteluo Biological Technology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Anteluo Biological Technology is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Anteluo Biological Technology has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Anteluo Biological Technology. This is due to cash flow or dividend data being unavailable. The share price is NT$24.84.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Anteluo Biological Technology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Anteluo Biological Technology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6564 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings () in TWD Not available
GTSM:6564 Share Price ** GTSM (2019-12-04) in TWD NT$24.84
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 24.09x
Taiwan, Province of China Market PE Ratio Median Figure of 1,431 Publicly-Listed Companies 16.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Anteluo Biological Technology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for Anteluo Biological Technology, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does Anteluo Biological Technology's expected growth come at a high price?
Raw Data
GTSM:6564 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 0.94x
Taiwan, Province of China Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.09x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Anteluo Biological Technology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Anteluo Biological Technology's assets?
Raw Data
GTSM:6564 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings () in TWD Not available
GTSM:6564 Share Price * GTSM (2019-12-04) in TWD NT$24.84
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 2.18x
Taiwan, Province of China Market PB Ratio Median Figure of 1,945 Publicly-Listed Companies 1.43x

* Primary Listing of Anteluo Biological Technology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Examine Anteluo Biological Technology's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Show me more potentially undervalued companies in the Pharmaceuticals industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Anteluo Biological Technology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Anteluo Biological Technology has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Anteluo Biological Technology expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anteluo Biological Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
35.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Anteluo Biological Technology expected to grow at an attractive rate?
  • Unable to compare Anteluo Biological Technology's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Anteluo Biological Technology's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare Anteluo Biological Technology's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:6564 Future Growth Rates Data Sources
Data Point Source Value (per year)
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 35.7%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 19.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 13.5%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6564 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings () See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Anteluo Biological Technology is high growth as no earnings estimate data is available.
  • Unable to determine if Anteluo Biological Technology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6564 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings () See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Anteluo Biological Technology Company Filings, last reported , and in Trailing twelve months (TTM) annual period rather than quarterly.

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Anteluo Biological Technology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Anteluo Biological Technology's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Anteluo Biological Technology's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Anteluo Biological Technology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Anteluo Biological Technology has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Anteluo Biological Technology performed over the past 5 years?

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Anteluo Biological Technology has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data. You can see them here.

Show me the analysis anyway

  • No data on Anteluo Biological Technology's last earnings update.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Anteluo Biological Technology's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if Anteluo Biological Technology's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Anteluo Biological Technology's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare Anteluo Biological Technology's 1-year growth to the TW Pharmaceuticals industry average as past earnings data has not been reported.
Earnings and Revenue History
Anteluo Biological Technology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Anteluo Biological Technology Company Filings, last reported , and in Trailing twelve months (TTM) annual period rather than quarterly.

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if Anteluo Biological Technology has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if Anteluo Biological Technology has efficiently used its assets last year compared to the TW Pharmaceuticals industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if Anteluo Biological Technology improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.

Next steps:

  1. Examine Anteluo Biological Technology'sAnteluo Biological Technology's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Past financial records are usually unavailable for companies that have just been established or recently publicly listed, which makes them inherently riskier. Take a look at a list of well-established companies here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Past performance checks
We assess Anteluo Biological Technology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Anteluo Biological Technology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Anteluo Biological Technology's financial health and their level of debt?

In this section we usually analyse Anteluo Biological Technology's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Anteluo Biological Technology has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information. You can see them here.

Show me the analysis anyway

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Anteluo Biological Technology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as Anteluo Biological Technology has not reported sufficient balance sheet data.
  • Unable to establish if Anteluo Biological Technology's long term commitments exceed its cash and other short term assets as Anteluo Biological Technology has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of Anteluo Biological Technology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if Anteluo Biological Technology has a high level of physical assets or inventory without balance sheet data.
  • Anteluo Biological Technology has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Anteluo Biological Technology Company Filings, last reported .

  • Anteluo Biological Technology has no debt.
  • Anteluo Biological Technology has not taken on any debt in the past 5 years.
  • Anteluo Biological Technology has no debt, it does not need to be covered by operating cash flow.
  • Anteluo Biological Technology has no debt, therefore coverage of interest payments is not a concern.

Next steps:

  1. Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Anteluo Biological Technology's financial data was last updated here.
  2. Companies with strong financial health are considered a less risky investment. Discover these stocks here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Financial health checks
We assess Anteluo Biological Technology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Anteluo Biological Technology has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Anteluo Biological Technology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Anteluo Biological Technology dividends.
If you bought NT$2,000 of Anteluo Biological Technology shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Anteluo Biological Technology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Anteluo Biological Technology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6564 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 2.7%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1328 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Anteluo Biological Technology has not reported any payouts.
  • Unable to verify if Anteluo Biological Technology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Anteluo Biological Technology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Anteluo Biological Technology has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Anteluo Biological Technology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Anteluo Biological Technology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Anteluo Biological Technology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Anteluo Biological Technology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Anteluo Biological Technology has no CEO, or we have no data on them.
Management Team
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Anteluo Biological Technology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Anteluo Biological Technology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Anteluo Biological Technology Co., Ltd. develops new vaccines. The company was founded in 2014 and is headquartered in Taiwan.

Details
Name: Anteluo Biological Technology Co., Ltd.
6564
Exchange: GTSM
Founded: 2014
NT$1,092,960,000
44,000,000
Website: http://
Address: Anteluo Biological Technology Co., Ltd.
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6564 Common Stock Taipei Exchange TW TWD 18. Sep 2018
Number of employees
Current staff
Staff numbers
0
Anteluo Biological Technology employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/12/04 15:42
End of day share price update: 2019/12/04 00:00
Last earnings filing: N/A
Last earnings reported: N/A
Last annual earnings reported: N/A


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.